Northwestern Medicine Amyloid Program | oneAMYLOIDOSISvoice
×
Or register here
Global Search

Trusted Resources: People & Places

Healthcare providers, researchers, and advocates

Back to Places / Academic & Health Care Centers
Northwestern Medicine Amyloid Program

Northwestern Medicine Amyloid Program

251 East Huron Street
Chicago, Illinois, United States
Phone   Web  

The Amyloid Program at Northwestern Medicine is among the largest comprehensive amyloid programs in the United States and world. Northwestern Medicine patients have access to the latest diagnostic tests, innovative treatments and leading-edge clinical trials for the treatment of all types of amyloidosis.

Due to the various types of amyloidosis, treatment options will be unique to each patient. Treatment options, discussed between you and your doctor, are dependent on what type of amyloid protein is produced, the parts of the body affected, the wishes of the patient and more.

 

Treatment options may include:

•  Medications to address symptoms associated with nerve damage, heart failure and/or kidney failure. The Amyloid Program at Northwestern Medicine has been actively involved in the development of several novel therapies that have recently become available to treat ATTR amyloidosis.

•  Well-tolerated chemotherapy drugs to suppress cells in the bone marrow that make AL amyloid proteins.

•  Stem cell transplant to achieve complete remission in some patients with AL amyloidosis.

•  Organ transplantation that may include heart, liver, or heart and liver, which may be curative for some patients diagnosed with the hereditary form of ATTR amyloidosis.

 

Related Content

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close

Community Key Collaborator

Support for this landing page is provided by an independent education grant from

Translation of this platform made possible through an independent education grant from

© 2025 rareLife solutions Inc.

To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences.
More information

The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.

Close